Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-α antibody

Journal of the European Academy of Dermatology and Venereology

Volumn 16, Issue 2, 2002, Pages 127-129

  Wollina, U ^a,b   Konrad, H ^b  

^a ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Infliximab; Psoriatic arthritis; Tumour necrosis factor

Indexed keywords

ANALGESIC AGENT; CHIMERIC ANTIBODY; CORTICOSTEROID DERIVATIVE; DITHRANOL; IMMUNOGLOBULIN A ANTIBODY; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; TRAMADOL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VITAMIN D DERIVATIVE;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL PATHWAY; DISEASE COURSE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LYMPHOCYTOPENIA; MALE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SKIN DISEASE; SKIN MANIFESTATION; SYMPTOM; ULTRAVIOLET B RADIATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHOTREXATE; PAIN MEASUREMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0036233794     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-3083.2002.00391.x     Document Type: Article

References (25)

1. kappaB
2. Cytokines in skin lesions of psoriasis
3. Elevated tumor necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions
4. Factors secreted by untreated psoriatic monocytes enhance neutrophil functions
5. Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: Relation to focal infection, disease activity and responses to treatments
6. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis
7. Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-alpha and their degranulation is associated with expression of ICAM-1 in the epidermis
8. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid
9. Macrophage-derived cytokine and nuclear factor kappa B p65 expression in synovial membrane and skin of patients with psoriatic arthritis
10. Anti-TNF-alpha therapy of rheumatoid arthritis: What have we learned?
11. Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy
12. TNF alpha is an effective therapeutic target for rheumatoid arthritis
13. Tumour necrosis factor-alpha blockade. A new era for effective management of rheumatoid arthritis
14. Anti-TNF agents for rheumatoid arthritis
15. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis
16. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy
17. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: The clinical experience with infliximab (REMICADE)
18. Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions
19. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial
20. Successful treatment of severe recalcitrant psoriasis with combination of infliximab and methotrexate
21. Interdisciplinary documentation of treatment side effects in oncology. Present status and perspectives
22. Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis
23. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate
24. Joint inflammation and cartilage destruction may occur uncoupled